Degludec outperforms glargine in curbing nocturnal hypoglycemia

05/6/2013 | Healio

Type 1 diabetes patients who received high-dose insulin degludec once daily showed lower rates of nocturnal hypoglycemia than their counterparts who took insulin glargine, a study showed. The findings were presented at the American Association of Clinical Endocrinologists annual meeting.

View Full Article in:

Healio

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL